Veozah in Oman

Veozah - overview

Veozah (fezolinetant) is manufactured by Astellas and indicated for moderate-to-severe vasomotor symptoms (hot flashes and night sweats) due to menopause. It is an oral tablet, 45 mg once daily approved by the US FDA in 2023 and may be accessible to patients in Oman through a Named Patient Program or personal-import pathway.

Access in Oman

Oman's MoH operates a personal-import pathway; volumes are smaller but the pathway is functional for rare-disease and specialty needs.

How Reserve Meds coordinates access in Oman

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Oman-specific eligibility.
3. Treating physician in Oman issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Veozah from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Oman.

Typical timeline for Oman

End-to-end, most requests are completed in 2-6 weeks. Oman's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Oman ask

• Is the pathway legal in Oman? Yes - it operates under Oman's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Oman able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Veozah in Oman

Join the Veozah waitlist